(Date:11/25/2009)... the course of a lifetime, the heart pumps some 25... order to do this, the muscle fibers of the heart ...eaded by Dr. Wolfgang Rottbauer, vice chair of the...ty Hospital (Chairman: Prof. Dr. H. A. Katus), has...stability of the smallest muscular unit, the sarco...
(Date:11/25/2009)... JOLLA, CAWhen you eat may be just as vital to you... Salk Institute for Biological Studies. Their expe... waning of thousands of genes in the liverthe body...food intake and not by the body,s circadian clock ...me determines the activity of a large number of ge...
(Date:11/24/2009)...Lupus Research Institute (LRI) today named 12 new ....6 million, recognize innovative work across a bro...or their creativity, novelty, and potential to dri...at, and cure the complex disease of systemic lupus...ed lupus researchers across the nation and include...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Feeding the clock 2Feeding the clock 3Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 1Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 2Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 3Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 4Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 5Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 6Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 1Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 2Study reveals 2 3 of prostate cancer patients do not need treatment 58130 1Study reveals 2 3 of prostate cancer patients do not need treatment 58130 2(Date:11/25/2009)... , , DURHAM, N.C., Nov. 25 /PRNewsw...nveiled the first energy-efficient, single-treatme...d from carbon nanotubes to Andhra Pradesh, Ministe...d other leaders in Hyderabad, India today. Initial...y (IIT) Kanpur, confirmed that the majority of the...
(Date:11/25/2009)... , , BEIJING, Nov. 25 /PRNewsw...g developer and provider of vaccines, announced to...t to establish Sinovac (Dalian) Vaccine,Technology... develop, produce,and commercialize human-use vacc...perience in developing and commercializing world-c...
(Date:11/24/2009)... , Ambassador to also Vis...mber 24, 2009 -- , , ,Who: David Appia, French Amb... and CEO of the Invest in France Agency, , , , ,W...ess to discuss recent pro-business initiatives ado...iscal and academic landscape for innovation and de...
(Date:11/24/2009)... , , ST. LOUIS, Nov. 24 /PRNewswire-Fi...AL ) will be presenting at the NASDAQ OMX conferen...on, 7:45 AM US/CST. Interested parties may listen ...le at http://inve s tor.sig m a a ldrich.c...ss this file. ,, About Sigma-Aldrich: Sig...
Breaking Biology Technology:North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3...D, N.J., Nov. 13 Covanta Holding,Corporation (NYS...n and,ownership of Energy-from-Waste and renewable...ended its agreement to purchase two biomass energy... and Indeck Energy,Services, Inc., Pursuant to th... these,two facilities for approximately $52 millio...
... Can Invest Simultaneously in Future Healthcare an...ternational Inc., one of the world,s largest and m...try leader in stem cell innovation, recently,renew...promise(R) the,largest private source of college f...Cell has been the only cord blood bank in the Unit...
...Calif., Nov. 13 Cardiogenesis,Corporation (Pink S...ucts,used in the treatment of patients suffering f...s for its third quarter ended September 30, 2008.,...hird quarter of 2008 totaled $2,618,000, a 25% dec...3,486,000. The lower revenue in,the current year q...
Other Biology Technology:Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 2Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 3Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 4Cryo-Cell Renews Upromise Industry-Exclusive Agreement 2Cryo-Cell Renews Upromise Industry-Exclusive Agreement 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 4Cardiogenesis Reports Third Quarter 2008 Results 2Cardiogenesis Reports Third Quarter 2008 Results 3Cardiogenesis Reports Third Quarter 2008 Results 4Cardiogenesis Reports Third Quarter 2008 Results 5Cardiogenesis Reports Third Quarter 2008 Results 6Cardiogenesis Reports Third Quarter 2008 Results 7FMK Negative Control from BioVision
Amino Acid Mixture, Complete from Promega
...vatives that have mutations in both the thioredoxi... genes, which greatly enhances disulfide bond form...pression in Origami(DE3) yielded 10-fold more acti...l expression levels were similar (1). Origami host...
Caspase-6 Inhibitor Z-VEID-FMK from BioVision
Biology Products: